Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic

Nickel et al describe a single-arm trial using dose-escalated hydroxyurea and regular transfusions to prevent complications of sickle cell anemia. Preliminary results suggest that a reduction in volume of red cell requirements may be achievable.

Detalles Bibliográficos
Autores principales: Nickel, Robert Sheppard, Margulies, Stefanie, Frazer, Brittany, Luban, Naomi L.C., Webb, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
Letter to Blood
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316219/
https://www.ncbi.nlm.nih.gov/pubmed/32403134
http://dx.doi.org/10.1182/blood.2020006582
Descripción
Sumario:Nickel et al describe a single-arm trial using dose-escalated hydroxyurea and regular transfusions to prevent complications of sickle cell anemia. Preliminary results suggest that a reduction in volume of red cell requirements may be achievable.

Ejemplares similares